HRP20050188B1 - Heterociklični aromatični spojevi koji se koriste kao sekretagogi hormona rasta - Google Patents
Heterociklični aromatični spojevi koji se koriste kao sekretagogi hormona rastaInfo
- Publication number
- HRP20050188B1 HRP20050188B1 HRP20050188AA HRP20050188A HRP20050188B1 HR P20050188 B1 HRP20050188 B1 HR P20050188B1 HR P20050188A A HRP20050188A A HR P20050188AA HR P20050188 A HRP20050188 A HR P20050188A HR P20050188 B1 HRP20050188 B1 HR P20050188B1
- Authority
- HR
- Croatia
- Prior art keywords
- sub
- growth hormone
- heterocyclic aromatic
- aromatic compounds
- compounds useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
Abstract
Novi heterociklični aromatični spojevi su korisni u stimuliranju endogene produkcije ili oslobađanju hormona rasta, spomenuti spojevi imaju opću strukturu formule I<BR/><IMAGE NAME="20050188_01" TYPE="jpg" CENTER=TRUE/><BR/>gdje su R<SUB>1</SUB>, R<SUB>1</SUB>', R<SUB>2</SUB>, R<SUB>3</SUB>, R<SUB>4</SUB>, Xa, Y, Z i n opisani u tekstu. Ovi spojevi su korisni u liječenju pretilosti, osteoporoze (povećanje gustoće kostiju) i u povećanju mišićne mase i mišićne snage.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40809902P | 2002-09-04 | 2002-09-04 | |
US49164503P | 2003-07-31 | 2003-07-31 | |
PCT/US2003/027513 WO2004021984A2 (en) | 2002-09-04 | 2003-09-02 | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20050188A2 HRP20050188A2 (en) | 2005-12-31 |
HRP20050188B1 true HRP20050188B1 (hr) | 2019-03-08 |
Family
ID=31981567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20050188AA HRP20050188B1 (hr) | 2002-09-04 | 2005-02-28 | Heterociklični aromatični spojevi koji se koriste kao sekretagogi hormona rasta |
Country Status (30)
Country | Link |
---|---|
US (8) | US7166596B2 (hr) |
EP (2) | EP2570414B1 (hr) |
JP (1) | JP4658600B2 (hr) |
KR (3) | KR101238041B1 (hr) |
CN (2) | CN1678372A (hr) |
AR (1) | AR041143A1 (hr) |
AU (1) | AU2003270065B2 (hr) |
BR (1) | BR0314024A (hr) |
CA (1) | CA2496842C (hr) |
CY (2) | CY1120250T1 (hr) |
DK (2) | DK1551511T5 (hr) |
ES (2) | ES2644265T3 (hr) |
GE (1) | GEP20074019B (hr) |
HR (1) | HRP20050188B1 (hr) |
HU (2) | HUE041936T2 (hr) |
IL (5) | IL166802A (hr) |
IS (1) | IS7719A (hr) |
LT (2) | LT1551511T (hr) |
MX (1) | MXPA05002301A (hr) |
MY (1) | MY139563A (hr) |
NO (1) | NO332370B1 (hr) |
NZ (1) | NZ538166A (hr) |
PE (1) | PE20040997A1 (hr) |
PL (1) | PL219563B1 (hr) |
PT (2) | PT1551511T (hr) |
RS (2) | RS55124B1 (hr) |
RU (1) | RU2382042C2 (hr) |
SI (2) | SI2570414T1 (hr) |
TW (2) | TWI330185B (hr) |
WO (1) | WO2004021984A2 (hr) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
AR043443A1 (es) * | 2003-03-07 | 2005-07-27 | Merck & Co Inc | Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios |
US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
AU2005272627A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
CA2576915A1 (en) * | 2004-08-18 | 2006-03-02 | Elixir Pharmaceuticals, Inc. | Growth-hormone secretagogues |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
MX2007003398A (es) * | 2004-09-27 | 2007-05-21 | Elixir Pharmaceuticals Inc | Sulfonamidas y sus usos. |
US8143425B2 (en) | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
US7579360B2 (en) * | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2006135860A1 (en) | 2005-06-10 | 2006-12-21 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
EP1757290A1 (en) | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
CN101374843B (zh) | 2005-12-21 | 2012-09-05 | 詹森药业有限公司 | 作为酪氨酸激酶调节剂的三唑并哒嗪 |
CN101421255A (zh) * | 2006-02-15 | 2009-04-29 | 艾博特公司 | 新的乙酰辅助a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合症中的应用 |
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
MX2008012617A (es) * | 2006-03-31 | 2008-10-10 | Novartis Ag | Compuestos organicos. |
WO2008006540A1 (en) * | 2006-07-12 | 2008-01-17 | Syngenta Participations Ag | Triazolopyridine derivatives as herbicides |
MY150731A (en) | 2006-11-27 | 2014-02-28 | Lundbeck & Co As H | Heteroaryl amide derivatives |
WO2008078725A1 (ja) * | 2006-12-26 | 2008-07-03 | Daiichi Sankyo Company, Limited | チアゼピン誘導体 |
JP2010518090A (ja) | 2007-02-09 | 2010-05-27 | トランザイム・ファーマ,インコーポレイテッド | 大環状グレリン受容体修飾因子およびその使用方法 |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
WO2008124153A1 (en) | 2007-04-10 | 2008-10-16 | H. Lundbeck A/S | Heteroaryl amide analogues as p2x7 antagonists |
WO2008130951A1 (en) * | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
WO2008151183A1 (en) * | 2007-06-04 | 2008-12-11 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
US9114138B2 (en) | 2007-09-14 | 2015-08-25 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones |
KR20100065191A (ko) | 2007-09-14 | 2010-06-15 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | 1,3-이치환된 4-(아릴-x-페닐)-1h-피리딘-2-온 |
KR20100080597A (ko) | 2007-09-14 | 2010-07-09 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | 1,3-이치환된-4-페닐-1h-피리딘-2-온 |
WO2009062676A2 (en) | 2007-11-14 | 2009-05-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
RU2510396C2 (ru) | 2008-09-02 | 2014-03-27 | Янссен Фармасьютикалз, Инк. | 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов |
US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
JP5535931B2 (ja) * | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
BRPI0921333A2 (pt) | 2008-11-28 | 2015-12-29 | Addex Pharmaceuticals Sa | derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
NZ596053A (en) | 2009-05-12 | 2013-05-31 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
SG176021A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
CA2784768C (en) | 2009-12-29 | 2015-02-03 | Eli Lilly And Company | Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia |
US8343977B2 (en) | 2009-12-30 | 2013-01-01 | Arqule, Inc. | Substituted triazolo-pyrimidine compounds |
CA2793313C (en) | 2010-04-02 | 2018-01-23 | Euroscreen Sa | Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
US8080568B1 (en) * | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
EP2446898A1 (en) * | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
PT2649069E (pt) | 2010-11-08 | 2015-11-20 | Janssen Pharmaceuticals Inc | Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2 |
EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JP6023814B2 (ja) | 2011-10-03 | 2016-11-09 | ユーロスクリーン エス.エー. | 選択的NK−3受容体拮抗薬としての新規なキラルN−アシル−5,6,7,(8位置換)−テトラヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン、その医薬組成物、NK−3受容体媒介性障害で使用する方法およびキラル合成 |
WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
WO2014144231A1 (en) | 2013-03-15 | 2014-09-18 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
US20140287997A1 (en) * | 2013-03-15 | 2014-09-25 | Massachusetts Institute Of Technology | Use of growth hormone or growth hormone receptor agonists to prevent or treat stress-sensitive psychiatric illness |
US10183948B2 (en) | 2013-03-29 | 2019-01-22 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
EA027570B1 (ru) | 2013-03-29 | 2017-08-31 | Огеда Са | НОВЫЕ N-АЦИЛ-(3-ЗАМЕЩЕННЫЕ)-(8-ЗАМЕЩЕННЫЕ)-5,6-ДИГИДРО-[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И МЕТОДЫ ИСПОЛЬЗОВАНИЯ ПРИ РАССТРОЙСТВАХ, ОПОСРЕДОВАННЫХ РЕЦЕПТОРОМ NK-3 |
ES2711143T3 (es) | 2013-03-29 | 2019-04-30 | Ogeda Sa | N-acil-(3-sustituido)-5,6,7,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor de NK-3, composición farmacéutica, métodos para su uso en los trastornos mediados por el receptor de NK-3 |
WO2014154897A1 (en) | 2013-03-29 | 2014-10-02 | Euroscreen Sa | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-METHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
DK3096790T3 (da) | 2014-01-21 | 2019-10-07 | Janssen Pharmaceutica Nv | Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse |
SI3431106T1 (sl) | 2014-01-21 | 2021-03-31 | Janssen Pharmaceutica Nv | Kombinacije, ki vsebujejo pozitivne alosterične modulatorje metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba |
US20170298070A1 (en) | 2014-09-25 | 2017-10-19 | Ogeda Sa | Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines |
WO2016104434A1 (ja) * | 2014-12-24 | 2016-06-30 | 武田薬品工業株式会社 | 複素環化合物 |
US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
CN106188063A (zh) * | 2015-05-08 | 2016-12-07 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途 |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
WO2017024406A1 (en) | 2015-08-11 | 2017-02-16 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
KR20180039117A (ko) | 2015-08-11 | 2018-04-17 | 네오메드 인스티튜트 | 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도 |
CA2994478C (en) | 2015-08-12 | 2023-10-03 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
WO2017127930A1 (en) * | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
EP3765459A1 (en) | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
JP2022549601A (ja) | 2019-09-18 | 2022-11-28 | 武田薬品工業株式会社 | ヘテロアリール血漿カリクレインインヒビター |
CN114728962A (zh) | 2019-09-18 | 2022-07-08 | 武田药品工业有限公司 | 血浆激肽释放酶抑制剂及其用途 |
JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
CN111533745A (zh) * | 2020-05-20 | 2020-08-14 | 成都药明康德新药开发有限公司 | 叔丁基-3-(氨基甲基)二氢-5h-三唑并二氮杂卓-8(9h)-甲酸基酯制法 |
CN112608315B (zh) * | 2020-12-14 | 2021-11-30 | 承德医学院 | 三唑并二氮杂卓类化合物及其制备方法及医药用途 |
EP4384167A1 (en) * | 2021-08-13 | 2024-06-19 | Mpc Therapeutics Sa | [1,2,4]triazolo[4,3-a]pyrimidin-7(8h)-one as mitochondrial pyruvate carrier inhibitors for use in the treatment of cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000054729A2 (en) * | 1999-03-12 | 2000-09-21 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3050525A (en) * | 1960-12-14 | 1962-08-21 | John B Bicking | Certain derivatives of s-triazolo [4, 3-a]-pyridine |
US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
GB1507462A (en) * | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
US3983234A (en) * | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
GB1586468A (en) * | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
US4255432A (en) * | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
GB8527052D0 (en) * | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
DE68922602T2 (de) | 1988-01-28 | 1995-12-07 | Polygen Holding Corp | Polypeptide mit hormonwachstumsbefreiender wirkung. |
AU628322B2 (en) | 1988-01-28 | 1992-09-17 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
FR2642069B1 (fr) * | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5179080A (en) | 1989-08-31 | 1993-01-12 | Clinical Homecare, Corp. | Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease |
US5216165A (en) * | 1990-10-03 | 1993-06-01 | American Home Products Corporation | N-substituted aminoquinolines as analgesic agents |
US5430150A (en) | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
CA2123728A1 (en) * | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
US5707798A (en) * | 1993-07-13 | 1998-01-13 | Novo Nordisk A/S | Identification of ligands by selective amplification of cells transfected with receptors |
EP0730578A4 (en) | 1993-11-24 | 1997-10-08 | Merck & Co Inc | COMPOUNDS CONTAINING AN INDOLYL GROUP AND THEIR USE FOR PROMOTING THE RELEASE OF GROWTH HORMONES |
DE4404183A1 (de) * | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5798337A (en) | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
EP0805816B1 (en) * | 1995-01-27 | 2004-07-28 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
EP0766966A3 (en) * | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
HUP9802580A3 (en) * | 1995-12-22 | 1999-03-29 | Novo Nordisk As | Compounds with growth hormone releasing properties |
US5869488A (en) * | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
AUPO864097A0 (en) * | 1997-08-19 | 1997-09-11 | Peplin Pty Ltd | Anti-cancer compounds |
DE69839056T2 (de) | 1997-09-05 | 2009-01-15 | Lead Chemical Co. Ltd. | Stereoisomere indolderivate, verfahren zu ihrer herstellung und ihre verwendung |
US6114310A (en) | 1998-01-23 | 2000-09-05 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
DE1071701T1 (de) * | 1998-04-14 | 2001-08-23 | Arena Pharm Inc | Non-endogene, konstitutiv aktivierte humane serotonin-rezeptoren und kleine molekülmodulatoren davon |
ATE279396T1 (de) | 1998-06-12 | 2004-10-15 | Sod Conseils Rech Applic | Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden |
US6140509A (en) * | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
IL140622A0 (en) | 1998-07-06 | 2002-02-10 | Bristol Myers Squibb Co | Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof |
US6358698B1 (en) * | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
JP2002531549A (ja) | 1998-12-04 | 2002-09-24 | ブリストル−マイヤーズ スクイブ カンパニー | カリウムチャネル・モジュレーターとしての3−置換−4−アリールキノリン−2−オン誘導体 |
US6150393A (en) * | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US20050148018A1 (en) * | 1999-10-07 | 2005-07-07 | David Weiner | Methods of identifying inverse agonists of the serotonin 2A receptor |
FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
US7022698B2 (en) * | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
KR20080059687A (ko) * | 2000-03-06 | 2008-06-30 | 아카디아 파마슈티칼스 인코포레이티드 | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 |
GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
JP4535728B2 (ja) * | 2001-12-28 | 2010-09-01 | アカディア ファーマシューティカルズ,インコーポレーテッド | モノアミン受容体調節因子としてのスピロアザ環式化合物 |
US7253186B2 (en) * | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) * | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
CN101780080B (zh) * | 2003-01-16 | 2014-06-04 | 阿卡蒂亚药品公司 | 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂 |
CN101031548B (zh) * | 2004-09-27 | 2011-04-06 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备 |
MX2008012617A (es) * | 2006-03-31 | 2008-10-10 | Novartis Ag | Compuestos organicos. |
-
2003
- 2003-08-28 MY MYPI20033269A patent/MY139563A/en unknown
- 2003-09-01 TW TW092124121A patent/TWI330185B/zh not_active IP Right Cessation
- 2003-09-01 TW TW099113061A patent/TWI362389B/zh not_active IP Right Cessation
- 2003-09-02 PL PL375882A patent/PL219563B1/pl unknown
- 2003-09-02 KR KR1020117010024A patent/KR101238041B1/ko active IP Right Grant
- 2003-09-02 RS YU20050186A patent/RS55124B1/sr unknown
- 2003-09-02 LT LTEP03751958.4T patent/LT1551511T/lt unknown
- 2003-09-02 LT LTEP12191757.9T patent/LT2570414T/lt unknown
- 2003-09-02 SI SI200332548T patent/SI2570414T1/sl unknown
- 2003-09-02 HU HUE03751958A patent/HUE041936T2/hu unknown
- 2003-09-02 EP EP12191757.9A patent/EP2570414B1/en not_active Expired - Lifetime
- 2003-09-02 HU HUE12191757A patent/HUE035498T2/en unknown
- 2003-09-02 BR BR0314024-5A patent/BR0314024A/pt not_active Application Discontinuation
- 2003-09-02 RU RU2005109545/04A patent/RU2382042C2/ru active
- 2003-09-02 RS YUP-2005/0186A patent/RS20050186A/sr unknown
- 2003-09-02 US US10/653,410 patent/US7166596B2/en not_active Expired - Lifetime
- 2003-09-02 MX MXPA05002301A patent/MXPA05002301A/es active IP Right Grant
- 2003-09-02 CN CNA038208644A patent/CN1678372A/zh active Pending
- 2003-09-02 GE GEAP20038721A patent/GEP20074019B/en unknown
- 2003-09-02 KR KR1020057003669A patent/KR20050040933A/ko not_active Application Discontinuation
- 2003-09-02 AU AU2003270065A patent/AU2003270065B2/en not_active Expired
- 2003-09-02 CA CA2496842A patent/CA2496842C/en not_active Expired - Lifetime
- 2003-09-02 PT PT03751958T patent/PT1551511T/pt unknown
- 2003-09-02 DK DK03751958T patent/DK1551511T5/da active
- 2003-09-02 ES ES12191757.9T patent/ES2644265T3/es not_active Expired - Lifetime
- 2003-09-02 ES ES03751958T patent/ES2706578T3/es not_active Expired - Lifetime
- 2003-09-02 PT PT121917579T patent/PT2570414T/pt unknown
- 2003-09-02 DK DK12191757.9T patent/DK2570414T3/en active
- 2003-09-02 SI SI200332585T patent/SI1551511T1/sl unknown
- 2003-09-02 KR KR1020107028594A patent/KR20110003592A/ko not_active Application Discontinuation
- 2003-09-02 JP JP2004534462A patent/JP4658600B2/ja not_active Expired - Lifetime
- 2003-09-02 WO PCT/US2003/027513 patent/WO2004021984A2/en active Application Filing
- 2003-09-02 CN CN201010154361A patent/CN101863886A/zh active Pending
- 2003-09-02 NZ NZ538166A patent/NZ538166A/en not_active IP Right Cessation
- 2003-09-02 EP EP03751958.4A patent/EP1551511B1/en not_active Expired - Lifetime
- 2003-09-04 AR ARP030103204A patent/AR041143A1/es active IP Right Grant
- 2003-09-04 PE PE2003000897A patent/PE20040997A1/es active IP Right Grant
-
2005
- 2005-02-10 IL IL166802A patent/IL166802A/en active IP Right Grant
- 2005-02-11 NO NO20050748A patent/NO332370B1/no not_active IP Right Cessation
- 2005-02-28 HR HRP20050188AA patent/HRP20050188B1/hr not_active IP Right Cessation
- 2005-02-28 IS IS7719A patent/IS7719A/is unknown
- 2005-11-14 US US11/272,898 patent/US7589102B2/en active Active
- 2005-11-14 US US11/273,169 patent/US7592354B2/en active Active
-
2008
- 2008-06-05 IL IL191960A patent/IL191960A/en active IP Right Grant
-
2009
- 2009-07-22 US US12/507,413 patent/US7910601B2/en not_active Expired - Lifetime
- 2009-09-03 US US12/507,430 patent/US7799801B2/en not_active Expired - Lifetime
-
2010
- 2010-08-09 US US12/852,610 patent/US7977353B2/en not_active Expired - Lifetime
-
2011
- 2011-01-23 IL IL210823A patent/IL210823A/en active IP Right Grant
- 2011-01-23 IL IL210824A patent/IL210824A0/en active IP Right Grant
- 2011-02-17 IL IL211281A patent/IL211281A/en active IP Right Grant
- 2011-05-20 US US13/112,015 patent/US8232291B2/en not_active Expired - Lifetime
-
2012
- 2012-06-11 US US13/493,448 patent/US8557841B2/en not_active Expired - Lifetime
-
2017
- 2017-11-15 CY CY20171101205T patent/CY1120250T1/el unknown
-
2018
- 2018-12-28 CY CY20181101404T patent/CY1121201T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000054729A2 (en) * | 1999-03-12 | 2000-09-21 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050188B1 (hr) | Heterociklični aromatični spojevi koji se koriste kao sekretagogi hormona rasta | |
MXPA02010452A (es) | Analogos de tetrahidroisoquinolina utiles como secretagogos de la hormona del crecimiento. | |
TR200401871T4 (tr) | Değiştirilen oktanoil amitlerin (octanoyl amides) hazırlanması | |
JP2004510493A5 (hr) | ||
MXPA04005038A (es) | Solvatos de paclitaxel. | |
ATE491436T1 (de) | Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen | |
TR200102967T2 (tr) | Substitüsyonlu azollar | |
DE29800975U1 (de) | Humeruskopfprothese | |
AR029157A1 (es) | Compuestos heterociclicos, aromaticos utiles como secretagogos de la hormona del crecimiento y las composiciones farmaceuticas que los contienen | |
BR0315644A (pt) | Piperazinil e diazapanil benzamidas e benzotioamidas | |
CY1108808T1 (el) | Ενωσεις μοτιλιδης | |
PT1432313E (pt) | Derivados de n-tio-nicotinamida e compostos relacionados para a utilização como pesticidas | |
IL132599A0 (en) | Substituted 3,3-diamino-2-propenenitriles their preparation and use | |
MX2007004259A (es) | Uso de compuestos organicos. | |
BR0012751A (pt) | Benzofuranos serotonérgicos | |
GB2454154A (en) | Aglet for attachment to a graft material | |
WO2002024181A3 (en) | The use of melatonin for induction of general anesthesia | |
BRPI0512708A (pt) | agentes promotores de crescimento de cabelo | |
DK1537203T3 (da) | ANVENDELSE AF DENDRITISKE CELLER (DC'er) DER UDTRYKKER INTERLEUKIN 12 (IL-12) | |
ATE392644T1 (de) | Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen | |
BR0214886A (pt) | Fenilalquinos | |
EA200600092A1 (ru) | Новые цитотоксические депсипептиды | |
UY26498A1 (es) | Pirroles sustituidos | |
AU2002359150A8 (en) | Therapeutic heterocycles | |
DK0589903T3 (da) | Aminoalkylsubstituerede 5-mercaptothiazoler, deres fremstilling og anvendelse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190809 Year of fee payment: 17 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200819 Year of fee payment: 18 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20210826 Year of fee payment: 19 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20220901 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20230902 |